RT Journal
A1 Senn L, Kovacsovics T, Tarr PE, Meylan P
T1 PEritoneal tuberculosis after imatinib therapy
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2009
FD February 9
VO 169
IS 3
SP 312
OP 316
DO 10.1001/archinternmed.2008.581
UL http://dx.doi.org/10.1001/archinternmed.2008.581
AB 
Imatinib mesylate, a selective inhibitor of the BCR-ABL tyrosine kinase gene, is now a standard therapy in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Recent studies have shown that imatinib alters T-cell–mediated immune responses,1- 4 raising the possibility of opportunistic infections associated with imatinib therapy. So far, few epidemiological data are available to support this hypothesis. We report herein a case of peritoneal tuberculosis (TB) following 4 months of imatinib therapy for CML.